Jazz Pharmaceuticals (JAZZ) said Monday it that Co-founder, Chairperson and Chief Executive Bruce Cozadd plans to retire.
Cozadd will retire as CEO upon the appointment of his replacement, which is expected by the end of 2025, but will continue as chairperson of the board, according to the company.
The company said its board will start a formal search process for a new CEO.
Jazz also said it remains on track to meet its full year 2024 total revenue guidance of between $4.0 billion and $4.1 billion.